Tatva Chintan Pharma Chem Limited will host a virtual one-to-one meeting with Ventura Securities Limited on July 30, 2026. The engagement is part of the company’s ongoing investor relations activities and aims to provide financial institutions and analysts with an opportunity to discuss the business based on publicly available data. Management emphasized that no unpublished price-sensitive information (UPSI) will be shared during the interaction, ensuring compliance with market regulations.

The intimation was submitted to the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ishwar Nayi, Company Secretary and Compliance Officer, signed the disclosure on July 24, 2026. The schedule is subject to change, though no alternative dates have been proposed in the filing.

Meeting Details

The company noted that all discussions will be confined to publicly available information. This approach aligns with standard regulatory practices for investor interactions, preventing any potential leakage of material non-public information. The details of the meeting are also available on the company’s website at www.tatvachintan.com .

Regulatory Compliance

Under Regulation 30 of the SEBI LODR Regulations, listed entities must promptly disclose schedules for meetings with analysts, financial institutions, or investors. This ensures transparency and equal access to information for all stakeholders. By explicitly stating that UPSI will not be discussed, Tatva Chintan Pharma reinforces its adherence to fair disclosure norms. The filing serves as a formal record for the exchanges and investors, maintaining the integrity of the capital markets.

Tatva Chintan Pharma Chem Limited reported a 54.8% year-on-year increase in consolidated net profit to ₹159.81 million for the quarter ended 30 June 2026, driven by higher operational income. Total income from operations rose 43% to ₹1,671 million from ₹1,168.64 million in the same period last year. EBITDA stood at ₹323 million, representing an 86% growth year-on-year and a 15% improvement over the previous quarter. The company’s earnings per share (EPS) on a consolidated basis improved to ₹6.83 for the quarter, compared to ₹2.84 in the corresponding period of the previous year.

The Board of Directors approved the financial results during its meeting held on 17 July 2026. Additionally, the Board approved the establishment of a new greenfield manufacturing facility involving an investment of approximately ₹200 crores. The groundbreaking ceremony is scheduled for 20 July 2026. The proposed facility is designed as a future-ready manufacturing platform to support the commercialization of new products and provide capacity for the company's next phase of growth. Management expects the facility to generate revenue of around ₹300 crores at peak utilization, targeting an asset turnover ratio of 1.2x to 1.5x.

Segment-wise Performance

Phase Transfer Catalysts contributed ₹428 million in revenue, a 38% growth quarter-on-quarter and 47% increase year-on-year. Structure Directing Agents reported ₹578 million in revenue, reflecting a 10% growth quarter-on-quarter and a 47% increase year-on-year. Pharma & Agro Intermediates and Specialty Chemicals delivered ₹584 million in revenue, a 63% growth quarter-on-quarter and a 25% growth year-on-year. Electrolyte Salts achieved ₹63 million in revenue, recording a 52% decline sequentially and a growth of 76% year-on-year.

Consolidated Financial Results

Standalone Financial Results

The extract of the financial results was filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.